Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
The data, spotted by an analyst at Cantor Fitzgerald, focused on concerns about potential side effects with the drug, called ...
Benzinga (Video) on MSN20h
Amgen Shares Drop 7% as Early Trial Data On Weight Loss Drug Raises Safety Concerns, Sparking Mixed Analyst ReactionsAmgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...
Amgen Inc.‘s AMGN stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...
Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after a ...
Amgen (AMGN) issued the following statement on the MariTide Phase 1 data. “As previously stated, Amgen does not see an association ...
The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 trial ...
Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...
BEIJING (Reuters) - China's embassy warned the Philippines to cease any "unilateral actions" after Manila brought in two new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback